TG Therapeutics Inc.
TGTX | NASDAQ
$57
-$0.16 (-0.28%)
Sep 22, 2026, 12:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 9.62 | 188.13 | 191.27 | -8.10 | -7.22 | -21.50 |
PEG Ratio | 0.01 | 2.38 | -1.80 | 0.18 | -0.83 | -0.92 |
PS Ratio | 6.98 | 13.29 | 10.38 | 575.19 | 375.58 | 39.47K |
PB Ratio | 6.64 | 19.67 | 15.11 | 27.34 | 10.59 | 11.55 |
P/FCF Ratio | -172.18 | -107.84 | -77.18 | -9.09 | -8.49 | -27.92 |
P/OCF Ratio | -173.67 | -107.96 | -77.18 | -9.09 | -8.50 | -27.97 |
OCF/S Ratio | -4.02 | -12.31 | -13.44 | -6.33K | -4.42K | -141.12K |
Debt / Equity Ratio | 0.40 | 1.14 | 0.69 | 1.42 | 0.33 | 0.08 |
Quick Ratio | 3.29 | 5.03 | 5.18 | 3.16 | 5.06 | 6.99 |
Current Ratio | 4.10 | 6.25 | 5.92 | 3.16 | 5.06 | 6.99 |
Asset Turnover | 0.58 | 0.57 | 0.71 | 0.01 | 0.02 | 0 |
Interest Coverage | 4.61 | 1.75 | 1.64 | -21.42 | -61.15 | -43.23 |
Return on Equity | 69.01% | 10.52% | 7.90% | -382.02% | -146.78% | -53.79% |
Return on Assets | 42.06% | 4.05% | 3.84% | -115.62% | -91.69% | -44.66% |
Return on Invested Capital | 13.54% | 7.85% | 7.22% | -153.80% | -108.88% | -48.69% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 83.66% | 88.30% | 93.95% | 90.48% | 88.19% | 100% |
Net Profit Margin | 72.56% | 7.11% | 5.42% | -8.04K% | -5.2K% | -183.8K% |
Pretax Profit Margin | 17.43% | 7.78% | 5.59% | -8.04K% | -5.2K% | -183.8K% |
Operating Profit Margin | 20.01% | 12.74% | 8.83% | -7.84K% | -5.15K% | -180K% |
FCF Margin | -4.05% | -12.33% | -13.44% | -6.33K% | -4.43K% | -141.36K% |
EBITDA Margin | 21.80% | 15.17% | 11.17% | -7.65K% | -5.11K% | -179.39K% |
Add to Watchlist
Select watchlists to add or remove TGTX